SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-034792
Filing Date
2021-06-28
Accepted
2021-06-28 16:15:42
Documents
13
Period of Report
2021-06-28
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abio-8k_20210628.htm   iXBRL 8-K 37868
2 EX-3.1 abio-ex31_47.htm EX-3.1 81382
  Complete submission text file 0001564590-21-034792.txt   271919

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA abio-20210628.xsd EX-101.SCH 5796
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE abio-20210628_lab.xml EX-101.LAB 20229
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE abio-20210628_pre.xml EX-101.PRE 12099
6 EXTRACTED XBRL INSTANCE DOCUMENT abio-8k_20210628_htm.xml XML 3656
Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 211053555
SIC: 2835 In Vitro & In Vivo Diagnostic Substances